As GSK Triples Capacity On Flu Drug Relenza, Royalties Trickle In For Aussie Originator Biota
This article was originally published in PharmAsia News
Executive Summary
PERTH, Australia - GlaxoSmithKline's announcement that it will triple its manufacturing capacity of antiviral Relenza is good news for Australian biotech Biota, the developer of the first-in-class neuraminidase inhibitor for which Biota receives 7 percent royalties on global sales
You may also be interested in...
Relenza Originator Aussie Biotech Biota Reports $37 Million In Royalties From GSK
PERTH, Australia - Melbourne-based Relenza developer Biota reported record-breaking royalties of $37.7 million from GlaxoSmithKline for FY2009, almost double the amount it reported a year ago
Relenza Originator Aussie Biotech Biota Reports $37 Million In Royalties From GSK
PERTH, Australia - Melbourne-based Relenza developer Biota reported record-breaking royalties of $37.7 million from GlaxoSmithKline for FY2009, almost double the amount it reported a year ago
Cash-pretty Australian Biotech Biota Returns $20 Million To Shareholders
PERTH, Australia - Just days after unveiling positive results from Phase III trials on its second-generation flu treatment laninamivir, co-developed with Daiichi Sankyo, Aussie Biotech Biota announced Aug. 13 that it would issue AU$20 million to its shareholders